<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40087560</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2261</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>BMC cardiovascular disorders</Title><ISOAbbreviation>BMC Cardiovasc Disord</ISOAbbreviation></Journal><ArticleTitle>Effects of diltiazem and metoprolol on levels of high-sensitivity troponin I in patients with permanent atrial fibrillation: a randomized trial.</ArticleTitle><Pagination><StartPage>181</StartPage><MedlinePgn>181</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">181</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12872-025-04574-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">High-sensitive (hs-) cardiac troponin assays provide prognostic information in atrial fibrillation (AF) patients. Few studies have explored the impact of long-term rate control therapy on levels of troponin in AF patients without coronary heart disease and heart failure. This substudy of the RATe control in Atrial Fibrillation (RATAF) II study aimed to compare the effects of six months' treatment with diltiazem and metoprolol on hs-troponin I (TnI) levels both at rest and during exercise testing in patients with permanent AF.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a parallel-group, randomized, investigator-blinded clinical trial. The cohort consisted of 93 patients (28 women, mean age 71&#x2009;&#xb1;&#x2009;7 years) with symptomatic, permanent AF with preserved left ventricular systolic function and no coronary heart disease. Participants were randomized in a 1:1 ratio to receive either diltiazem 360 mg (n&#x2009;=&#x2009;49) or metoprolol 100 mg (n&#x2009;=&#x2009;44) once daily for six months. Blood tests were drawn at rest and during peak exercise testing at baseline, one month and six months' treatment. This research has been supported by grants from the South-Eastern Norway Regional Health Authority and Vestre Viken Hospital Trust.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Six months' treatment with diltiazem and metoprolol significantly lowered the heart rate at rest and peak exercise. Both treatment groups exhibited a decrease in hs-TnI levels at rest (diltiazem p&#x2009;=&#x2009;0.008, metoprolol p&#x2009;=&#x2009;0.03) and peak exercise (diltiazem p&#x2009;&lt;&#x2009;0.001, metoprolol p&#x2009;=&#x2009;0.004) at six months compared to baseline levels, with no significant differences observed between the groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with permanent AF, six months of rate control therapy with diltiazem or metoprolol lowered levels of hs-TnI. Further research is warranted to determine whether this reduction translates into an improved prognosis.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">NCT02695992. Registration date: 2015-04-28.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Enge</LastName><ForeName>Katrine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Research, B&#xe6;rum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulimoen</LastName><ForeName>Sara Reinvik</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Medical Research, B&#xe6;rum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enger</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Research, B&#xe6;rum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onarheim</LastName><ForeName>Sophia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Research, B&#xe6;rum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olufsen</LastName><ForeName>Mona</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Research, B&#xe6;rum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pripp</LastName><ForeName>Are Hugo</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Oslo Centre of Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinsvik</LastName><ForeName>Trude</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, B&#xe6;rum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Ringerike Hospital, Vestre Viken Hospital Trust, H&#xf8;nefoss, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hetland</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Diakonhjemmet Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tveit</LastName><ForeName>Arnljot</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Research, B&#xe6;rum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway. Arnljot.tveit@vestreviken.no.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. Arnljot.tveit@vestreviken.no.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02695992</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cardiovasc Disord</MedlineTA><NlmUniqueID>100968539</NlmUniqueID><ISSNLinking>1471-2261</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EE92BBP03H</RegistryNumber><NameOfSubstance UI="D004110">Diltiazem</NameOfSubstance></Chemical><Chemical><RegistryNumber>GEB06NHM23</RegistryNumber><NameOfSubstance UI="D008790">Metoprolol</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019210">Troponin I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058671">Adrenergic beta-1 Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004110" MajorTopicYN="Y">Diltiazem</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008790" MajorTopicYN="Y">Metoprolol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019210" MajorTopicYN="Y">Troponin I</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000889" MajorTopicYN="Y">Anti-Arrhythmia Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="Y">Heart Rate</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058671" MajorTopicYN="Y">Adrenergic beta-1 Receptor Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005080" MajorTopicYN="N">Exercise Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="Y">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atrial fibrillation</Keyword><Keyword MajorTopicYN="N">Beta-blockers</Keyword><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Calcium channel blockers</Keyword><Keyword MajorTopicYN="N">Cardiac troponins</Keyword><Keyword MajorTopicYN="N">Rate control</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: The RATAF II trial was approved by the Norwegian Medicines Agency and the Regional Ethics Committee (2015/1302). The trial was registered at www.clinicaltrials.gov (NCT02695992). Each patient gave informed consent in agreement with the Helsinki Declaration before participating in any study-related activity. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>16</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>16</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>15</Day><Hour>0</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>3</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40087560</ArticleId><ArticleId IdType="pmc">PMC11907844</ArticleId><ArticleId IdType="doi">10.1186/s12872-025-04574-2</ArticleId><ArticleId IdType="pii">10.1186/s12872-025-04574-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J. 2013;34(20):1475&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">23386711</ArticleId></ArticleIdList></Reference><Reference><Citation>Blankenberg S, Salomaa V, Makarova N, Ojeda F, Wild P, Lackner KJ, et al. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. Eur Heart J. 2016;37(30):2428&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4982535</ArticleId><ArticleId IdType="pubmed">27174290</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304(22):2503&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5621378</ArticleId><ArticleId IdType="pubmed">21139111</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggers KM, Lind L, Ahlstr&#xf6;m H, Bjerner T, Ebeling Barbier C, Larsson A, et al. Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects. Eur Heart J. 2008;29(18):2252&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18606612</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace TW, Abdullah SM, Drazner MH, Das SR, Khera A, McGuire DK, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation. 2006;113(16):1958&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">16618821</ArticleId></ArticleIdList></Reference><Reference><Citation>Rienstra M, Yin X, Larson MG, Fontes JD, Magnani JW, McManus DD, et al. Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation. Am Heart J. 2014;167(1):109-15.e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3884900</ArticleId><ArticleId IdType="pubmed">24332149</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D, et al. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014;129(6):625&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">24226808</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta K, Pillarisetti J, Biria M, Pescetto M, Abu-Salah TM, Annapureddy C, et al. Clinical utility and prognostic significance of measuring troponin I levels in patients presenting to the emergency room with atrial fibrillation. Clin Cardiol. 2014;37(6):343&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6649457</ArticleId><ArticleId IdType="pubmed">24700276</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr&#xf6;m-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">32860505</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, et al. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol. 2014;63(1):52&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">24055845</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijazi Z, Lindb&#xe4;ck J, Alexander JH, Hanna M, Held C, Hylek EM, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016;37(20):1582&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4875560</ArticleId><ArticleId IdType="pubmed">26920728</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijazi Z, Oldgren J, Lindb&#xe4;ck J, Alexander JH, Connolly SJ, Eikelboom JW, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet (London, England). 2016;387(10035):2302&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">27056738</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijazi Z, Oldgren J, Lindb&#xe4;ck J, Alexander JH, Connolly SJ, Eikelboom JW, et al. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018;39(6):477&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837352</ArticleId><ArticleId IdType="pubmed">29069359</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns H, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">39210723</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulimoen SR, Enger S, Norseth J, Pripp AH, Abdelnoor M, Arnesen H, et al. Improved rate control reduces cardiac troponin T levels in permanent atrial fibrillation. Clin Cardiol. 2014;37(7):422&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6649449</ArticleId><ArticleId IdType="pubmed">24700386</ArticleId></ArticleIdList></Reference><Reference><Citation>Horjen AW, Ulimoen SR, Enger S, Norseth J, Seljeflot I, Arnesen H, et al. Troponin I levels in permanent atrial fibrillation-impact of rate control and exercise testing. BMC Cardiovasc Disord. 2016;16:79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4855853</ArticleId><ArticleId IdType="pubmed">27142292</ArticleId></ArticleIdList></Reference><Reference><Citation>Enge K, Tveit A, Enger S, Onarheim S, Pripp AH, R&#xf8;nningen PS, et al. Diltiazem reduces levels of NT-proBNP and improves symptoms compared with metoprolol in patients with permanent atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. 2024;10(6):515&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">38702844</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340: c332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844940</ArticleId><ArticleId IdType="pubmed">20332509</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulimoen SR, Enger S, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, et al. Calcium channel blockers improve exercise capacity and reduce N-terminal pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J. 2014;35(8):517&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">24135831</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, et al. Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart (British Cardiac Society). 2014;100(15):1193&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">24794140</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyama K, Giugliano RP, Berg DD, Ruff CT, Jarolim P, Tang M, et al. Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2021;42(17):1698&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8599897</ArticleId><ArticleId IdType="pubmed">33760027</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijazi Z, Lindahl B, Oldgren J, Andersson U, Lindback J, Granger CB, et al. Repeated measurements of cardiac biomarkers in atrial fibrillation and validation of the ABC stroke score over time. Journal of the American Heart Association. 2017;6(6):e004851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669148</ArticleId><ArticleId IdType="pubmed">28645934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation. 2012;125(13):1605&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">22374183</ArticleId></ArticleIdList></Reference><Reference><Citation>Aim&#xe9;-Semp&#xe9; C, Folliguet T, R&#xfc;cker-Martin C, Krajewska M, Krajewska S, Heimburger M, et al. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol. 1999;34(5):1577&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">10551709</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnab&#xe9;-Heider F, Walsh S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324(5923):98&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2991140</ArticleId><ArticleId IdType="pubmed">19342590</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeremias A, Gibson CM. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med. 2005;142(9):786&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">15867411</ArticleId></ArticleIdList></Reference><Reference><Citation>White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? J Am Coll Cardiol. 2011;57(24):2406&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21658560</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannitsis E, Katus HA. Cardiac troponin level elevations not related to acute coronary syndromes. Nat Rev Cardiol. 2013;10(11):623&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">23979214</ArticleId></ArticleIdList></Reference><Reference><Citation>Parwani AS, Boldt LH, Huemer M, Wutzler A, Blaschke D, Rolf S, et al. Atrial fibrillation-induced cardiac troponin I release. Int J Cardiol. 2013;168(3):2734&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23623668</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">20231232</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshide S, Fukutomi M, Eguchi K, Watanabe T, Kabutoya T, Kario K. Change in high-sensitive cardiac troponin T on hypertensive treatment. Clin Exp Hypertens. 2013;35(1):40&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">22631049</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagodzinski A, Neumann JT, Ojeda F, S&#xf6;rensen NA, Wild P, M&#xfc;nzel T, et al. Cardiovascular biomarkers in hypertensive patients with medical treatment-results from the randomized TEAMSTA protect I trial. Clin Chem. 2017;63(12):1877&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">28904053</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyama K, Giugliano RP, Ruff CT, Berg DD, Jarolim P, Tang M, et al. Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation. Eur J Heart Fail. 2023;25(6):832&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">36987929</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>